Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2709Lung Neoplasms 2267Small Cell Lung Carcinoma 452Breast Neoplasms 394Neoplasms 348Colorectal Neoplasms 245Ovarian Neoplasms 208Pancreatic Neoplasms 196Melanoma 196Prostatic Neoplasms 187Adenocarcinoma of Lung 184Neoplasm Metastasis 177Head and Neck Neoplasms 175Mesothelioma, Malignant 152Esophageal Neoplasms 144Carcinoma, Renal Cell 142Stomach Neoplasms 141Colonic Neoplasms 138Urinary Bladder Neoplasms 124Mesothelioma 121Squamous Cell Carcinoma of Head and Neck 115Uterine Cervical Neoplasms 97Sarcoma 86Brain Neoplasms 86Kidney Neoplasms 82Carcinoma, Hepatocellular 71Liver Neoplasms 68Adenocarcinoma, Bronchiolo-Alveolar 68Rectal Neoplasms 64Pleural Effusion, Malignant 64

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Small Cell Lung Cancer Recurrent × Thoracic × Clear all
NCT03823118 2023-02-23

S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

Taizhou Hospital

Phase 2 Completed
48 enrolled
Thoracic

Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡